Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.

about

Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q42289084

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Phospho-PRAS40

@nl

Phospho-PRAS40(Thr246) predict ...... tive metastatic breast cancer.

@en

type

Item

label

Phospho-PRAS40

@nl

Phospho-PRAS40(Thr246) predict ...... tive metastatic breast cancer.

@en

prefLabel

Phospho-PRAS40

@nl

Phospho-PRAS40(Thr246) predict ...... tive metastatic breast cancer.

@en

P1476

Phospho-PRAS40(Thr246) predict ...... tive metastatic breast cancer.

@en

P2093

Hongqiang Chen

http://www.w3.org/2001/XMLSchema#string

Hongyan Wu

http://www.w3.org/2001/XMLSchema#string

Kai Yuan

http://www.w3.org/2001/XMLSchema#string

Mingwen Jiao

http://www.w3.org/2001/XMLSchema#string

Rongzhan Fu

http://www.w3.org/2001/XMLSchema#string

Yulong Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

P304

785-789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2014.2744

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271535184

http://www.w3.org/2001/XMLSchema#string

P698

25621052

http://www.w3.org/2001/XMLSchema#string

P932

4301480

http://www.w3.org/2001/XMLSchema#string